SCHEDULE: Vanguard Group Reports Zero Stake in ACADIA Pharma Post-Realignment

The Vanguard Group has reported 0% beneficial ownership in ACADIA Pharmaceuticals Inc. following an internal realignment where subsidiaries will now report separately.

Summary

• The Vanguard Group filed an Amendment No. 9 to Schedule 13G regarding its beneficial ownership in ACADIA Pharmaceuticals Inc.
• As of the filing, The Vanguard Group reports 0.00 shares with sole or shared voting and dispositive power, representing 0% of the class of Common Stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions, in accordance with SEC Release No. 34-39538 (January 12, 1998).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing. It reflects a change in reporting structure for The Vanguard Group, not a change in investment thesis or performance for ACADIA Pharmaceuticals Inc.

Positives

• The filing clarifies The Vanguard Group's reporting structure, indicating a more granular disclosure of beneficial ownership by its subsidiaries.

Negatives

• The filing does not indicate any negative operational or financial developments for ACADIA Pharmaceuticals Inc.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding ACADIA Pharmaceuticals Inc.'s business or financial performance, nor does it indicate any future investment intentions from The Vanguard Group.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment."
• "In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment."
• "Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes that such internal realignments are common among large asset managers like Vanguard, often aimed at streamlining reporting or optimizing operational structures. This specific filing reflects a change in how Vanguard's various entities report their holdings, rather than a change in investment strategy towards ACADIA Pharmaceuticals Inc.

Comparison to Industry Standards

• This filing is an administrative update regarding beneficial ownership reporting, not a performance or operational report. Therefore, direct comparisons to industry standards for company performance or project results are not applicable. It aligns with standard SEC reporting requirements for institutional investors.

Stakeholder Impact

• Shareholders of ACADIA Pharmaceuticals Inc. should note that The Vanguard Group, Inc. itself no longer directly reports beneficial ownership, but its underlying investment strategies through subsidiaries are stated to remain the same.
• Investment professionals tracking institutional ownership will need to monitor filings from Vanguard's disaggregated subsidiaries for a complete picture of Vanguard's overall holdings in ACADIA.

Next Steps

• Investment professionals tracking institutional ownership will need to monitor future Schedule 13G/A filings from Vanguard's disaggregated subsidiaries for a complete picture of Vanguard's overall holdings in ACADIA Pharmaceuticals Inc.

Key Dates

Keywords

ACADIA Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Ownership, Common Stock, Internal Realignment